KFP-H008

KFP-H008 is an orally active potassium-competitive acid blocker. KFP-H008 inhibits gastric acid secretion through blocking H+-K+-ATPase. KFP-H008 reduces ethanol-induced gastric ulcer index and malonaldehyde as well as proinflammatory cytokine expression in vivo. KFP-H008 downregulates p-p38 MAPK and p65 NF-κB expression. KFP-H008 blocks histamine-stimulated acid secretion in rat and dog models. KFP-H008 can be studied in research on acid-related disease, such as ethanol-induced gastric ulcer and gastric epithelial cell damage[1][2][3].

1876453-55-2

12352005

ATP Synthase; p38 MAPK

MAPK/ERK Pathway; Membrane Transporter/Ion Channel

Inflammation/Immunology

O=S(=O)(C=1C=NC=CC1)N2C=C(C=C2C3=CC=C4NC=CC4=C3)CNC

C19H18N4O2S

366.44

[1]Su M, et al., Anti-ulcerogenic effect of KFP-H008 against ethanol-induced gastric ulcer via p38 MAPK/NF-κB pathway. RSC Adv. 2019 Jun 4;9 (31) :17591. |[2]Lu B, et al., Fertility and early embryonic development toxicity and toxicokinetic study of KFP-H008 in Sprague-Dawley rats. Birth Defects Res. 2022 May;114 (8) :304-313. |[3]Li CY, et al., KFP-H008 blocks gastric acid secretion through inhibiting H+-K+-ATPase. Eur J Pharmacol. 2017 Sep 5;810:112-119.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-180348/

Reference compound1

No Development Reported